Corcept submits relacorilant marketing authorization application to EMA

Corcept Therapeutics (CORT) has submitted a marketing authorization application to the European Medicines Agency for relacorilant to treat patients with platinum-resistant ovarian cancer. Corcept’s MAA submission is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. The FDA is reviewing Corcept’s application to market relacorilant in the United States to treat patients with platinum-resistant ovarian cancer. The FDA’s Prescription Drug User Fee Act target action date is July 11, 2026.